Molecular Partners AG Files 6-K with Financials
Ticker: MOLN · Form: 6-K · Filed: Oct 31, 2024 · CIK: 1745114
Sentiment: neutral
Topics: financial-reporting, interim-financials, press-release
Related Tickers: MPRS
TL;DR
MPRS drops 6-K with Q3 financials, check it out.
AI Summary
Molecular Partners AG filed a Form 6-K on October 31, 2024, to furnish a press release and unaudited condensed consolidated interim financial statements for the nine months ended September 30, 2024. The filing includes financial data and operational updates for the period.
Why It Matters
This filing provides investors with updated financial information and operational highlights for Molecular Partners AG, crucial for assessing the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing (6-K) providing updated financial statements and a press release, not indicating new significant risks.
Key Players & Entities
- Molecular Partners AG (company) — Registrant
- October 31, 2024 (date) — Filing date
- September 30, 2024 (date) — Reporting period end date
FAQ
What type of financial statements are being furnished in this 6-K?
The filing furnishes condensed consolidated interim financial statements (unaudited) as of, and for the three and nine months ended, September 30, 2024.
What is the primary purpose of this Form 6-K filing?
The primary purpose is to furnish a press release issued by the Registrant on October 31, 2024, and the condensed consolidated interim financial statements for the period ending September 30, 2024.
What is the Commission File Number for Molecular Partners AG?
The Commission File Number for Molecular Partners AG is 001-40488.
When was the press release mentioned in the filing issued?
The press release was issued on October 31, 2024.
Does Molecular Partners AG file annual reports under Form 20-F?
Yes, the filing indicates with a checkmark that the registrant files annual reports under cover of Form 20-F.
Filing Stats: 286 words · 1 min read · ~1 pages · Grade level 12.8 · Accepted 2024-10-31 16:00:58
Filing Documents
- a6kq32024.htm (6-K) — 19KB
- prfor6-ksecfiling.htm (EX-99.1) — 33KB
- q32024financialstatements.htm (EX-99.2) — 227KB
- image_0a.jpg (GRAPHIC) — 19KB
- 0001745114-24-000019.txt ( ) — 307KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Molecular Partners AG (Registrant) Date October 31, 2024 s PATRICK AMSTUTZ Name Patrick Amstutz Title Chief Executive Officer